Institut Bergonie

Bordeaux, New Aquitaine FR-33076

2 studies enrolling now · 7 studies all time

What they study most

Acute T Cell Leukemia Lymphoma, Advanced Solid Tumors, Bone Cancer, Bone Metastases, Bone Neoplasm, Breast Neoplasms, Cancer, Dedifferentiated Liposarcoma, Endometrial Cancer, Fallopian Tube Cancer, Low-grade Serous Ovarian Cancer, Malignancies

Studies at this site

• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers — Recruiting now
• A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer — Recruiting now
• A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab — Recruiting now
• A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers — Running, not enrolling
• 9-ING-41 in Patients With Advanced Cancers — Running, not enrolling
• Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma — Stopped early
• A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer — Completed